Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status-Reference-Cited by-同舟云学术

Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status

Published:2002-10 Issue:5 Volume:11 Page:419-429
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Thomson C.S.,Twelves C.J.,Mallon E.A.,Leake R.E.

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference13 articles.

1. Ovarian ablation in early breast cancer: overview of the randomised trials

2. Polychemotherapy for early breast cancer: an overview of the randomised trials

3. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer;Lippman;J Clin Oncol,1978

4. Standardisation of steroid receptor assays in human breast cancer ii;Koenders;Eur J Can Clin Oncol,1983

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reproduction;Medical Radiology;2022

2. Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China;Translational Breast Cancer Research;2020-07

3. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer;Molecular and Clinical Oncology;2019-08-20

4. Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing;Breast Disease;2019

5. Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists;Breast Cancer;2018-06-29